Abstracts tagged "Scleroderma"

Abstract Number: 739 • 2019 ACR/ARP Annual Meeting
Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?
Mislav Radic¹, Rebecca Overbury ² and Tracy Frech ³, ¹University Hospital Split, Split, Croatia, ²University of Utah, Departments of Pediatrics and Internal Medicine, Division of Rheumatology, Salt Lake City, UT, ³Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: The fingers have specialized structural and functional features for thermoregulation, and are the most common areas of Raynaud’s phenomenon (RP) in systemic sclerosis (SSc).…
Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
Madelon Vonk¹, Oliver Distler ², Daniel Furst ³, Eric Hachulla ⁴, Sindhu Johnson ⁵, Shervin Assassi ⁶, Leslie Meng ⁷, Manuel Quaresma ⁸, Margarida Alves ⁸, Emmanuelle Clerisme-Beaty ⁸ and Wim Wuyts ⁹, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³University of California, Los Angeles, CA, ⁴Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ⁵Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…
Abstract Number: 2611 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cells in Scleroderma: A Systematic Review
Rossana Mejia-Romero ¹, Natalia Aguilera², Juan Pablo Alzate-Granados ³, C Escobar -Soto ⁴, Claudia Mendoza-Pinto ⁵, Mario García-Carrasco ⁵ and Adriana Rojas-Villarraga ⁶, ¹Center for Arthritis and Rehabilitation (CAYRE IPS) ,University of Barcolena, Bogotá, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogota, Distrito Capital de Bogota, Colombia, ⁴TRUSTEM, Bogotá, Distrito Capital de Bogota, Colombia, ⁵Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE CMNMAC - CIBIOR, Instituto Mexicano del Seguro Social. Department of Rheumatology and Immunology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico, ⁶Fundacion Universitaria de Ciencias de La Salud-FUCS. Hospital Infantil Universitario San José., Bogotá, Distrito Capital de Bogota, Colombia
Background/Purpose: Scleroderma (systemic scleroderma or systemic sclerosis, SSc), is a highly heterogeneous autoimmune disease of unknown etiology, with a high rate of therapeutic failure and…
Abstract Number: 866 • 2019 ACR/ARP Annual Meeting
Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
Edward Stern ¹, Lauren Host ¹, K. Jane Escott ², Peter Gilmour ², Ivy Wanjiku ³, Rachel Ochiel ³, Aine Burns ¹, Robert Unwin ¹, Voon Ong ⁴ and Christopher Denton⁵, ¹University College London, London, United Kingdom, ²AstraZeneca, London, United Kingdom, ³Royal Free Hospital, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) causes scleroderma renal crisis (SRC) and chronic kidney disease (CKD). A previous open label trial of bosentan suggested possible benefit for…
Abstract Number: 1644 • 2019 ACR/ARP Annual Meeting
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana¹, Kristin Highland ², Martina Gahlemann ³, Christopher Denton ⁴, Aryeh Fischer ⁵, Maureen Mayes ⁶, Virginia Steen ⁷, Dinesh Khanna ⁸, Yannick Allanore ⁹, Mannaig Girard ¹⁰, Margarida Alves ¹¹, Susanne Stowasser ¹¹ and Oliver Distler ¹², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁵University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Georgetown University, Washington, D.C., USA, Georgetown, ⁸Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Patients with diffuse cutaneous systemic sclerosis (dcSSc) are at greater risk of developing interstitial lung disease (ILD) than patients with limited cutaneous systemic sclerosis…
Abstract Number: 2615 • 2019 ACR/ARP Annual Meeting
Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis
Tatiana Nevskaya ¹, Yuxuan Jiang ¹, Mianbo Wang ² and Janet Pope³, ¹University of Western Ontario, London, ON, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Western University, London, ON, Canada
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc), thought to be more commonly found among the limited cutaneous (lcSSc) compared…
Abstract Number: 868 • 2019 ACR/ARP Annual Meeting
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study
Robyn Domsic¹, Maureen Laffoon ¹, Balasubramani Goundappa ², Thomas Medsger ¹, Robert Lafyatis ¹ and Steven Wisniewski ¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Epidemiology Data Center, Pittsburgh, PA
Background/Purpose: Statins have pleiotropic effects felt to influence in their beneficial cardiovascular effects. These include increased nitric oxide production and improved endothelial function, modulation of…
Abstract Number: 1645 • 2019 ACR/ARP Annual Meeting
Comparison of Automated Capture and Analysis System of Sublingual Microvessels and Nailfold Videocapillarscopy for Microvascular Assessment in Systemic Sclerosis
Mislav Radic¹, Julie Thomas ² and Tracy Frech ³, ¹University Hospital Split, Split, Croatia, ²University of Utah, Division of Rheumatology, Salt Lake City, UT, ³Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: Similar to nailfold videocapillaroscopy (NVC), automated capture and analysis of sublingual microvessel segments (intravital microscopy) can define vasculopathy, and distinguish systemic sclerosis (SSc) patients…
Abstract Number: 2616 • 2019 ACR/ARP Annual Meeting
Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort
Mirette Habib¹, Sara Jaafar ¹, Annie Park ¹, Suiyuan Huang ¹, Wen Ye ¹, Vivek Nagaraja ¹, Eric White ¹, Kevin Flaherty ² and Dinesh Khanna ³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial Lung Disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. Forced Vital Capacity (FVC, recorded as %…
Abstract Number: 1042 • 2019 ACR/ARP Annual Meeting
Thy-1 (CD90) as a Novel Marker for Tracking in Vivo Skin Fibrosis
Benjamin Korman¹, Ananta Paine ², Stacey Duemmel ³, Marc Nuzzo ³ and Christopher Ritchlin ², ¹University of Rochester Medical Center, Rochester, NY, ²Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ³University of Rochester, Rochester, NY
Background/Purpose: Thy-1 (CD90) is a cell surface marker which is found primarily on fibroblasts and whose expression has previously been shown to correlate with pathologic…
Abstract Number: 1646 • 2019 ACR/ARP Annual Meeting
Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution
Mamoun Elnagar¹, Yasser Radwan ¹, Mohamed Elwazir ², Reto Kurmann ², Rekha Mankad ¹, Thomas Osborn ¹, Ashima Makol ¹, Leroy Griffing ³, Cynthia Crowson ² and Alicia Hinze ¹, ¹Mayo Clinic Minnesota, Rochester, MN, ²Mayo Clinic Minnesota, Rochester, ³Mayo Clinic Arizona, Scottsdale
Background/Purpose: Systemic sclerosis (SSc) associated heart involvement remains ill-defined, with non-ischemic systolic heart failure, conduction defects, and arrhythmias often included in the definition in clinical…
Abstract Number: 2750 • 2019 ACR/ARP Annual Meeting
Development and Preliminary Validation of a Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Patients with Systemic Sclerosis
Robert Fairchild¹, Diana Yang ², Melody Chung ¹, Laurel Sharpless ¹, Shufeng Li ³ and Lorinda Chung ¹, ¹Stanford University, Palo Alto, CA, ²Santa Clara Valley Medical Center, Palo Alto, CA, ³Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc), and screening, characterization, and monitoring of disease activity are important for therapeutic…
Abstract Number: 1049 • 2019 ACR/ARP Annual Meeting
Induction of a Profibrotic Phenotype in Normal Dermal Fibroblasts by Expression of PIM1 Kinase and Demonstration of Antifibrotic Effects of Inhibition of PIM Kinases in Systemic Sclerosis Dermal Fibroblasts
Danielle Pomante ¹, Sergio Jimenez ² and Sonsoles Piera-Velazquez¹, ¹Thomas Jefferson University, Philadelphia, PA, ²Jefferson Institute of Molecular Medicine and Division of Connective Tissue Diseases, Thomas Jefferson University, Philadelphia, PA, Philadelphia, PA
Background/Purpose: There is an urgent unmet need for effective therapeutic approaches for Systemic Sclerosis (SSc), a systemic autoimmune disease characterized by progressive fibrosis of skin…
Abstract Number: 1647 • 2019 ACR/ARP Annual Meeting
The Collaborative National Quality and Efficacy Registry for Scleroderma: Data Completion Outcomes from a Multicenter United States Cohort Using Guideline-Based Registry Practices
Victoria Shanmugam¹, Tracy Frech ², Virginia Steen ³, Laura Hummers ⁴, Ami Shah ⁵, Elana Bernstein ⁶, Dinesh Khanna ⁷, Jessica Gordon ⁸, Flavia Castelino ⁹, Lorinda Chung ¹⁰, Faye Hant ¹¹, Emily Startup ¹², John VanBuren ¹², Luke Evnin ¹³ and Shervin Assassi ¹⁴, ¹George Washington University, Georgetown, DC, ²Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ³Georgetown University, Washington, D.C., USA, Georgetown, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ⁵Johns Hopkins Hospital, Baltimore, MD, ⁶Division of Rheumatology, Columbia University, New York, NY, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁸Hospital for Special Surgery, New York, NY, ⁹Harvard University, Boston, MA, ¹⁰Stanford University, Palo Alto, CA, ¹¹Medical University of South Carolina, Charleston, SC, ¹²University of Utah, Salt Lake City, UT, ¹³Scleroderma Research Foundation, San Francisco, CA, ¹⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX
Background/Purpose: The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5…
Abstract Number: 2916 • 2019 ACR/ARP Annual Meeting
Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population
Pravitt Gourh ¹, Sarah Safran², Steven Boyden ³, Ami Shah ⁴, Maureen Mayes ⁵, Ayo Doumatey ⁶, Amy Bentley ⁶, Daniel Shriner ⁶, Robyn Domsic ⁷, Thomas Medsger Jr ⁸, Paula Ramos ⁹, Richard Silver ¹⁰, Virginia Steen ¹¹, John Varga ¹², Vivien Hsu ¹³, Lesley Saketkoo ¹⁴, Elena Schiopu ¹⁵, Dinesh Khanna ¹⁶, Jessica Gordon ¹⁷, Brynn Kron ¹⁸, Lindsey Criswell ¹⁹, Heather Gladue ²⁰, Chris Derk ²¹, Elana Bernstein ²², S Louis Bridges ²³, Victoria Shanmugam ²⁴, Kathleen Kolstad ²⁵, Lorinda Chung ²⁶, Suzanne Kafaja ²⁷, Reem Jan ²⁸, Marcin Trojanowski ²⁹, Avram Goldberg ³⁰, Benjamin Korman ³¹, Peter Steinbach ³², Settara Chandrasekharappa ⁶, James Mullikin ⁶, Adebowale Adeyemo ⁶, Charles Rotimi ⁶, Frederick Wigley ³³, Daniel Kastner ³⁴, Francesco Boin ³⁵, Elaine Remmers ⁶ and Theresa Alexander ³⁶, ¹National Institutes of Rheumatology, Bethesda, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, MD, ³University of Utah, SALT LAKE CITY, UT, ⁴Johns Hopkins Hospital, Baltimore, MD, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁶National Human Genome Research Institute (NHGRI), Bethesda, MD, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Pittsburg School of Medicine, Pittsburg, PA, ⁹Medical University of South Carolina, Charleston, ¹⁰Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹¹Georgetown University, Washington, D.C., USA, Georgetown, ¹²Northwestern University, Chicago,, IL, ¹³Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ¹⁴New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ¹⁵Department of Rheumatology, University of Michigan, Ann Arbor, ¹⁶Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹⁷Hospital for Special Surgery, New York, NY, ¹⁸University of California San Francisco, San Francisco, CA, ¹⁹University of California, San Francisco, San Francisco, ²⁰Arthritis & Osteoporosis Consultants Of The Carolinas, Charlotte, NC, ²¹University of Pennsylvania, Philadelphia, PA, ²²Division of Rheumatology, Columbia University, New York, NY, ²³University of Alabama at Birmingham, Birmingham, ²⁴George Washington University, Georgetown, DC, ²⁵Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, ²⁶Stanford University, Palo Alto, CA, ²⁷Department of Medicine. Rheumatology Division. UCLA, Los Angeles, CA, ²⁸University of Chicago Pritzker School of Medicine, Chicago, IL, ²⁹Boston University Medical Center, Boston, MA, ³⁰New York University Langone Medical Center, New York, NY, ³¹University of Rochester Medical Center, Rochester, NY, ³²Center for Molecular Modeling, Center for Information Technology, National Institutes of Health, Bethesda, MD, ³³Johns Hopkins University, Division of Rheumatology, Baltimore, ³⁴National Institutes of Health, Bethesda, MD, ³⁵UCSF, San Francisco, CA, ³⁶University of Maryland, College Park, MD
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a heterogeneous disease that is divided into limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) forms based on the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.